ClinicalTrials.gg
CompletedNCT00751400Updated Aug 25, 2015Results posted

Naproxen Sodium Extended-Release Actual Use Study

A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) in Pain, sponsored by Bayer. Completed at 24 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-08-25.

Sponsored by Bayer · Phase 3 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
497
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.

Enrollment
3rd of 25
497 · median 100
Started
2008
with 2 others
Phase 3
5 of 25
none open now
Registered
3rd of 25
by date
Lead sponsor
9 of 25
Bayer

Among the 25 studies testing naproxen in Pain, this one is the 3rd largest by enrollment, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 3rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing naproxen in Pain, or all of them as a file.
02

Study summary

The purpose of this Study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.

Read the detailed description

Issues on adverse event data are addressed in the Adverse Event section.

The following acronyms and abbreviations were used in the results section.

  • General Educational Development (GED)
03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Non-prescription
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self report use of Over The Counter (OTC) analgesics
  • Able to read and understand English
  • Provide written (subjects 12- 17 years of age provide written as sent and/ or parent or legal guardian provide written consent)
  • Purchase the product

Exclusion criteria

Exclusion Criteria:

  • Have participated in a study involving OTC analgesics in the last 12 months
  • They or someone else in the household work for a market research company, an advertising agency, a public relations firm, pharmaceutical company, as a healthcare professional, or as part of a health care practice
  • Have a history of known allergies to nonsteroidal anti-inflammatory drugs (NSAIDs) (i.e., Naproxen, Ibuprofen, etc) or Aspirin
  • Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
  • (Female subjects) are pregnant or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
497 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium ER (BAYH6689)

    subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever

    Drug: Naproxen Sodium ER (BAYH6689)

Interventions

06

What researchers measure

Primary outcomes

  1. Use Days With One or More Misuse Occasions

    Misuse occasion: any reported use of 2 or more tablets within a 22 hour period (included use of 2 tablets in 1 dose or the use of 1 tablet at one time and 1+ tablets at a later time within the same 22 hour period). Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in 1 use-day. If a subject reported product consumption on 3 different days this resulted in 3 use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

    Time frame: 1 month

Secondary outcomes

  1. Dosing Occasions With One and More Than One Tablet Taken

    Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

    Time frame: 1 month

  2. Use Days With and Without Next Dose Less Than 22 Hours Later

    Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in one use-day. If a subject reported product consumption on three different days this resulted in three use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

    Time frame: 1 month

  3. Number of Subjects With and Without More Than One Tablet Taken Per Dose

    Time frame: 1 month

  4. Number of Subjects With and Without Next Dose Less Than 22 Hours Later

    This Outcome is a measure of subjects while Outcome Measure 3 provides the outcome as a measure of cumulative number of use-days for all subjects involved.

    Time frame: 1 month

  5. Number of Subjects With and Without More Than 660 mg at Least Once

    This measure refers to number of subjects that exceeded 660 mg of naproxen sodium per day at least once during the reporting period. The maximum dose (660 mg) may have been exceeded with one dose (if a subject consumed two tablets in one dosing occasion) or may have been exceeded throughout the course of a use-day (if a subject took one tablet in one dosing occasion and then later in the same day took one or more tablets in another dosing occasion).

    Time frame: 1 month

  6. Average Daily Dose

    Time frame: 1 month

  7. Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days

    This measure is reporting how many subjects exceeded the label limit for consecutive days of study drug dosing

    Time frame: 1 month

  8. Number of Total Dosing Occasions Per Subject

    Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

    Time frame: 1 month

  9. Number of Dosing Occasions Per Subject That Exceeded 660 mg

    Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

    Time frame: 1 month

07

Results

Posted May 17, 2011
Limitations and caveats
No control group, detailed data collected for up to 10 days during 1 month followup, data recall by subjects may vary

Participant flow

Recruitment for the study was conducted using newspaper ads, direct mailing, in-store pharmacy posters, and flyers. Potential subjects who learned about the study through local advertising were directed to call a toll-free number (call center at the CRO (Contract Research Organization)) where minimal screening questions were asked.

Participant flow — Overall Study
MilestoneNaproxen Sodium ER (BAYH6689)
Started497
Subjects provided drug497
Subjects consumed drug485
Subjects provided detailed use data467
Completed487
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryUse Days With One or More Misuse Occasions

Misuse occasion: any reported use of 2 or more tablets within a 22 hour period (included use of 2 tablets in 1 dose or the use of 1 tablet at one time and 1+ tablets at a later time within the same 22 hour period). Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in 1 use-day. If a subject reported product consumption on 3 different days this resulted in 3 use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

Time frame:
1 month
Reported as:
Number · days
Use Days With One or More Misuse Occasions
daysNaproxen Sodium ER (BAYH6689)
use days without a misuse occasion2112
use days with a misuse occasion294
SecondaryDosing Occasions With One and More Than One Tablet Taken

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Time frame:
1 month
Reported as:
Number · dosing occasions
Dosing Occasions With One and More Than One Tablet Taken
dosing occasionsNaproxen Sodium ER (BAYH6689)
only one tablet taken2500
more than one tablet taken66
SecondaryUse Days With and Without Next Dose Less Than 22 Hours Later

Use-days were calculated based on days in which there was subject-reported product consumption, meaning that if a tablet was consumed on a day this resulted in one use-day. If a subject reported product consumption on three different days this resulted in three use-days. The cumulative expression of use-days is the total number of use-days reported by all subjects with follow up data.

Time frame:
1 month
Reported as:
Number · days
Use Days With and Without Next Dose Less Than 22 Hours Later
daysNaproxen Sodium ER (BAYH6689)
no dose less than 22 hours later2175
at least one dose less than 22 hours later231
SecondaryNumber of Subjects With and Without More Than One Tablet Taken Per Dose
Time frame:
1 month
Reported as:
Number · participants
Number of Subjects With and Without More Than One Tablet Taken Per Dose
participantsNaproxen Sodium ER (BAYH6689)
never took more than one tablet per dose440
took more than one tablet per dose27
SecondaryNumber of Subjects With and Without Next Dose Less Than 22 Hours Later

This Outcome is a measure of subjects while Outcome Measure 3 provides the outcome as a measure of cumulative number of use-days for all subjects involved.

Time frame:
1 month
Reported as:
Number · participants
Number of Subjects With and Without Next Dose Less Than 22 Hours Later
participantsNaproxen Sodium ER (BAYH6689)
no doses less than 22 hours later359
at least one dose less than 22 hours later108
SecondaryNumber of Subjects With and Without More Than 660 mg at Least Once

This measure refers to number of subjects that exceeded 660 mg of naproxen sodium per day at least once during the reporting period. The maximum dose (660 mg) may have been exceeded with one dose (if a subject consumed two tablets in one dosing occasion) or may have been exceeded throughout the course of a use-day (if a subject took one tablet in one dosing occasion and then later in the same day took one or more tablets in another dosing occasion).

Time frame:
1 month
Reported as:
Number · participants
Number of Subjects With and Without More Than 660 mg at Least Once
participantsNaproxen Sodium ER (BAYH6689)
not more than 660 mg344
more than 660 mg at least once123
SecondaryAverage Daily Dose
Time frame:
1 month
Reported as:
Mean · mg
Average Daily Dose
mgNaproxen Sodium ER (BAYH6689)
Average Daily Dose722 ± 233.4
SecondaryNumber of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days

This measure is reporting how many subjects exceeded the label limit for consecutive days of study drug dosing

Time frame:
1 month
Reported as:
Number · participants
Number of Subjects That Have Taken Study Drug on More Than 10 Consecutive Days and Not on More Than 10 Consecutive Days
participantsNaproxen Sodium ER (BAYH6689)
not more than 10 consecutive days376
more than 10 consecutive days109
SecondaryNumber of Total Dosing Occasions Per Subject

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Time frame:
1 month
Reported as:
Mean · dosing occasions
Number of Total Dosing Occasions Per Subject
dosing occasionsNaproxen Sodium ER (BAYH6689)
Number of Total Dosing Occasions Per Subject5.5 ± 3.7
SecondaryNumber of Dosing Occasions Per Subject That Exceeded 660 mg

Dosing occasion means a single occasion in which a subject reported consuming the study drug. Multiple dosing occasions were possible throughout one use-day. For example, if a subject took one tablet at 6 am this would result in one dosing occasion. If the same subject took one tablet later that same day at 8 pm this would result in a second dosing occasion.

Time frame:
1 month
Reported as:
Mean · dosing occasions
Number of Dosing Occasions Per Subject That Exceeded 660 mg
dosing occasionsNaproxen Sodium ER (BAYH6689)
Number of Dosing Occasions Per Subject That Exceeded 660 mg0.6 ± 1.6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium ER (BAYH6689)—3/485 (0.6%)111/485 (22.9%)
Most frequent serious events
Most frequent serious events
EventNaproxen Sodium ER (BAYH6689)
CellulitisInfections and infestations1/485
SepsisInfections and infestations1/485
Renal impairmentRenal and urinary disorders1/485
Most frequent other events
Showing 10 of 68
Most frequent other events
EventNaproxen Sodium ER (BAYH6689)
DyspepsiaGastrointestinal disorders10/485
HeadacheNervous system disorders10/485
NauseaGastrointestinal disorders8/485
Abdominal pain upperGastrointestinal disorders7/485
DiarrhoeaGastrointestinal disorders7/485
ConstipationGastrointestinal disorders6/485
Pain in extremityMusculoskeletal and connective tissue disorders6/485
ArthralgiaMusculoskeletal and connective tissue disorders5/485
FlatulenceGastrointestinal disorders4/485
NasopharyngitisInfections and infestations4/485

Baseline characteristics

Age, Continuous
Age, Continuous(years)Naproxen Sodium ER (BAYH6689)
Mean49.8 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium ER (BAYH6689)
Female292
Male205
Education
Education(participants)Naproxen Sodium ER (BAYH6689)
8th grade or less6
Some high school21
High school graduate, GED, or certificate119
Some college or technical school185
College graduate117
Post-graduate degree49
Missing0
Literacy
Literacy(participants)Naproxen Sodium ER (BAYH6689)
Normal437
Low56
No REALM Score4
Prior Analgesic Use
Prior Analgesic Use(participants)Naproxen Sodium ER (BAYH6689)
Heavy148
Regular349
Race
Race(participants)Naproxen Sodium ER (BAYH6689)
White399
Black56
Hispanic3
Asian8
Other31
Missing0
08

Study locations

24 sites
  • Anaheim, California 92801, United States
  • Oceanside, California 92054, United States
  • San Dimas, California 91773, United States
  • Overland Park, Kansas 66209, United States
  • Anoka, Minnesota 55303, United States
  • Blaine, Minnesota 55443, United States
  • Elk River, Minnesota 55330, United States
  • St. Francis, Minnesota 55070, United States
  • St. Louis Park, Minnesota 55426, United States
  • Belton, Missouri 64012, United States
  • Savannah, Missouri 64485, United States
  • St. Joseph, Missouri 64504, United States
  • Cary, North Carolina 27513, United States
  • Chapel Hill, North Carolina 27514, United States
  • Raleigh, North Carolina 27606, United States
  • Raleigh, North Carolina 27612, United States
  • Bountiful, Utah 84010, United States
  • Ogden, Utah 84401, United States
  • Salt Lake City, Utah 84102, United States
  • Syracuse, Utah 84075, United States
  • West Jordan, Utah 84088, United States
  • Kenmore, Washington 98028, United States
  • Seattle, Washington 98148, United States
  • Snohomish, Washington 98290, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 6 months after primary completion. A results delay was requested in Dec 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2008
First posted
Sep 12, 2008
Start
Jul 2008
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Dec 9, 2009
Results first posted
May 17, 2011
Last update
Aug 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00751400
Lead sponsor
Bayer
Collaborators
Pegus Research, Inc.
Responsible party
Sponsor
First posted
Sep 12, 2008
Start date
Jul 2008
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
May 17, 2011
Last update
Aug 25, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion